Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Safety and Efficacy of CM-101 in Subjects With Primary Sclerosing Cholangitis (The SPRING Study)

NCT04595825 is registered in ClinicalTrials.gov with ChemomAb Ltd. as lead sponsor.

NCT NCT04595825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04595825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Safety and Efficacy of CM-101 in Subjects With Primary Sclerosing Cholangitis (The SPRING Study)
Lead sponsor
ChemomAb Ltd.
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2020
Completion date
January 10, 2025
Enrollment
77 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

primary sclerosing cholangitis